Lukas Rob
Lukas Rob is an expert in Oncology at Fakultní nemocnice Královské Vinohrady (Czechia). As of October 2026, ScienceLeadR ranks Lukas Rob in the top 1% of experts worldwide for Uterine Diseases, Urogenital Neoplasms and Genital Neoplasms, Female. Lukas Rob has authored 241 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 3 of them ongoing. SLR score: 792 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Gynecology - Obstetrics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 241
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Heterogeneity in Risk of Recurrent CIN2+ Among Women With Genotype-Specific HPV Detected After Excision: A Cohort Study. PMID 42685315 — incidence, conization, cohort studies, human papillomavirus 16, genotype, therapeutics, alphapapillomavirus, papillomavirus infections, human papillomavirus viruses | J Low Genit Tract Dis | 2026 | 0 |
| A case report: false hCG trail: dysgerminoma imitates gestational trophoblastic disease. PMID 42389208 — trophoblasts, trophoblastic neoplasms, ovary, neoplasms, gestational trophoblastic disease, drug therapy, signs and symptoms, dysgerminoma, diagnosis, therapeutics, trophoblastic tumor, placental site, chemotherapy | AJOG Glob Rep | 2026 | 0 |
| Clinically relevant histopathological features and biomarkers in endometrial cancer. PMID 42113616 — molecular targeted therapy, heart failure, neoplasms, obstetrics, rna, circular, biomarkers, therapeutics, prognosis, endometrial neoplasms | Ceska Gynekol | 2026 | 0 |
| Ectopic pregnancy management and treatment strategies: A nationwide survey of Czech gynecological facilities. PMID 41999233 — pregnancy, pregnancy, ectopic, therapeutics, pregnancy, interstitial, methotrexate, pregnancy, tubal | Womens Health (Lond) | 2026 | 0 |
| NKG2A inhibition promotes NK cell-CD8 + T cell interactions to improve anticancer immunity in ovarian carcinoma. PMID 41998001 — cells, killer cells, natural, ovary, neoplasms, carcinoma, non-small-cell lung, ovarian neoplasms, cell communication, immunity, t-lymphocytes | Nat Commun | 2026 | 0 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Comparing Paclitaxel Carboplatin Oregovomab versus Paclitaxel Carboplatin Placebo in Patients with Advanced Ovarian Cancer 2024-519218-30-00 — paclitaxel, ovary, neoplasms, drug therapy, immunotherapy, ovarian neoplasms, therapeutics, carboplatin, fallopian tubes, chemotherapy, carcinoma | Phase 3 | Active not recruiting | 2021 |
| Epidemiological Factors and Optimization of Conservative Approaches to Precancerous Lesions of Female Reproductive Organs NCT06967740 — conservative treatment, vaccines, uterine cervical neoplasms, neoplasms, uterine cervical dysplasia, risk factors, wounds and injuries, female, women | N/A | Recruiting | 2024 |
| Study of Pembrolizumab (MK 3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK 3475 B21 KEYNOTE B21 ENGOT en11 GOG 3053) NCT04634877 — radiotherapy, cells, b7-h1 antigen, lewy bodies, parkinson disease, docetaxel, paclitaxel, hypersensitivity, brachytherapy, neoplasms, double-blind method, drug therapy, respect, drug-related side effects and adverse reactions, chemotherapy, adjuvant, therapeutics, carboplatin, ligands, cell death, endometrial neoplasms, chemotherapy | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map